City Therapeutics raises $230M in upsized Nasdaq IPO
City Therapeutics (CTY) raised $230M in its Nasdaq IPO, selling 12.8M shares at $18 each, including underwriters' option. The biotech firm focuses on RNA interference therapeutics. Shares began trading on Oct. 16, 2026. Joint book-runners include Goldman Sachs, Jefferies, Stifel, and Oppenheimer.
How this was made
The 30-second read
Why it matters
The capital raise provides runway for development programs, while the market debut creates liquidity and visibility for the stock.
Market read
A sizable biotech IPO adds a new tradable asset, likely drawing interest from growth‑oriented investors and biotech funds.
What to watch
Potential regulatory hurdles for its pipeline and the need for further financing beyond the IPO proceeds.
Background
City Therapeutics is a clinical‑stage company focused on RNA interference therapies, entering public markets to fund its pipeline.
Ticker impact
City Therapeutics completed a $230M Nasdaq IPO, issuing 12.78M shares at $18 each, marking its first public offering.
upward pressure as investors seek exposure to a newly listed RNA‑interference biotech
First‑day trading often sees a pop for high‑growth biotech IPOs; the sizable raise and market enthusiasm support a short‑term upside.
Market effects
Adds a new listed player to the RNA‑interference biotech sector, potentially boosting sector interest and valuations.
Strengthens the Nasdaq biotech roster, modestly supporting US biotech market sentiment.
Limited to biotech investors; no broader macro impact.
Counterpoint
If the IPO is over‑priced at $18, the stock could face immediate selling pressure and a post‑IPO dip.
Key entities
- underwriterGoldman Sachs & Co. LLC
Joint book‑running manager for the IPO.
- underwriterJefferies
Joint book‑running manager for the IPO.
